GMAB Valuation

Genmab A/S

Add to Watchlist

Advanced Chart

21.650

-0.02(-0.092%)1D

Overview
Forecast
Valuation
Earnings

GMAB Relative Valuation

GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMAB is overvalued; if below, it's undervalued.

Historical Valuation

Genmab A/S (GMAB) is now in the Undervalued zone, suggesting that its current forward PE ratio of 14.30 is considered Undervalued compared with the five-year average of 44.71. The fair price of Genmab A/S (GMAB) is between 22.96 to 96.44 according to relative valuation methord. Compared to the current price of 21.67 USD , Genmab A/S is Undervalued By 5.63%.

Relative Value

Fair Zone

22.96-96.44

Current Price：21.67

5.63%

Undervalued

14.30

Trailing

Forward

7.74

EV/EBITDA

Genmab A/S. (GMAB) has a current EV/EBITDA of 7.74. The 5-year average EV/EBITDA is 32.45. The thresholds are as follows: Strongly Undervalued below -22.80, Undervalued between -22.80 and 4.82, Fairly Valued between 60.07 and 4.82, Overvalued between 60.07 and 87.70, and Strongly Overvalued above 87.70. The current Forward EV/EBITDA of 7.74 falls within the Historic Trend Line -Fairly Valued range.

8.52

EV/EBIT

Genmab A/S. (GMAB) has a current EV/EBIT of 8.52. The 5-year average EV/EBIT is 31.20. The thresholds are as follows: Strongly Undervalued below -9.86, Undervalued between -9.86 and 10.67, Fairly Valued between 51.73 and 10.67, Overvalued between 51.73 and 72.25, and Strongly Overvalued above 72.25. The current Forward EV/EBIT of 8.52 falls within the Undervalued range.

3.65

Genmab A/S. (GMAB) has a current PS of 3.65. The 5-year average PS is 11.63. The thresholds are as follows: Strongly Undervalued below -1.15, Undervalued between -1.15 and 5.24, Fairly Valued between 18.02 and 5.24, Overvalued between 18.02 and 24.41, and Strongly Overvalued above 24.41. The current Forward PS of 3.65 falls within the Undervalued range.

14.48

P/OCF

Genmab A/S. (GMAB) has a current P/OCF of 14.48. The 5-year average P/OCF is 35.03. The thresholds are as follows: Strongly Undervalued below -0.18, Undervalued between -0.18 and 17.42, Fairly Valued between 52.63 and 17.42, Overvalued between 52.63 and 70.24, and Strongly Overvalued above 70.24. The current Forward P/OCF of 14.48 falls within the Undervalued range.

14.53

P/FCF

Genmab A/S. (GMAB) has a current P/FCF of 14.53. The 5-year average P/FCF is 39.58. The thresholds are as follows: Strongly Undervalued below 6.33, Undervalued between 6.33 and 22.96, Fairly Valued between 56.20 and 22.96, Overvalued between 56.20 and 72.82, and Strongly Overvalued above 72.82. The current Forward P/FCF of 14.53 falls within the Undervalued range.

Genmab A/S (GMAB) has a current Price-to-Book (P/B) ratio of 2.63. Compared to its 3-year average P/B ratio of 4.57 , the current P/B ratio is approximately -42.46% higher. Relative to its 5-year average P/B ratio of 5.89, the current P/B ratio is about -55.30% higher. Genmab A/S (GMAB) has a Forward Free Cash Flow (FCF) yield of approximately 8.56%. Compared to its 3-year average FCF yield of 4.70%, the current FCF yield is approximately 82.35% lower. Relative to its 5-year average FCF yield of 3.79% , the current FCF yield is about 126.01% lower.

2.63

P/B

Median3y

4.57

Median5y

5.89

8.56

FCF Yield

Median3y

4.70

Median5y

3.79

Competitors Valuation Multiple

The average P/S ratio for GMAB's competitors is 4.83, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 3.65, which is -24.47% above the industry average. Given its robust revenue growth of 18.57%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Bristol-Myers Squibb Co

Vertex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

4.33

-3.70%

58.89B

Performance Decomposition

Market capitalization of GMAB decreased by 22.05% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 603.00M to 715.00M.

The secondary factor is the Margin Expansion, contributed -14.35%to the performance.

Overall, the performance of GMAB in the past 1 year is driven by Revenue Growth. Which is more sustainable.

18.57%

603.00M → 715.00M

Revenue Growth

-14.35%

31.84 → 27.27

Margin Expansion

-26.27%

16.26 → 11.99

P/E Change

-22.05%